Source / episode info
- **Episode:**14
- **Title:**Divine Intervention Episode 14-Comprehensive Immuno Pharmacology and The Monoclonal Alphabet.
- **Published:**2018-04-02
- Source:Episode page
One-liner
This episode comprehensively reviews cytokine signaling (IL-4/Th2; IL-12/Th1), immune cell function (ADCC vs opsonization), hematopoiesis factors (GCSF, TPO, EPO), and the pharmacology of monoclonal antibodies targeting key inflammatory pathways (TNF-, CD20, C5, IL-6R) and immunosuppressive agents.
High-yield summary
- T Cell Differentiation: Th1 cells are driven by IL-12 and mediate cell-mediated immunity; Th2 cells are driven by IL-4 and mediate antibody-mediated immunity.
- Immune Clearance Mechanisms: Natural Killer (NK) cells perform Antibody-Dependent Cellular Cytotoxicity (ADCC), while macrophages performing phagocytosis of coated pathogens is called Opsonization.
- Hematopoiesis Regulation: Platelet production requires Thrombopoietin (TPO) or IL-11 analogs; Granulocyte production uses GCSF.
- Monoclonal Antibody Targets: Drugs like Rituximab target CD20 on B cells, while Aculizumab targets C5, preventing complement-mediated hemolysis in PNH.
- Immunosuppression: Calcineurin inhibitors (Cyclosporine/Tacrolimus) inhibit calcineurin to block IL-2 signaling; mTOR inhibitors (Sirolimus) block the downstream pathway by inhibiting mTOR.
- Inflammatory Axis Control: The Th17 axis can be blocked either upstream (anti-IL-23, e.g., Ostequinumab) or downstream (anti-IL-17, e.g., Secukinumab).
Learning objectives
- Differentiate between T helper 1 (Th1) and T helper 2 (Th2) immune responses based on key cytokines (IL-12 vs IL-4).
- Identify the specific targets and clinical uses of monoclonal antibodies in autoimmune/malignancy settings (e.g., anti-CD20, anti-TNF-\alpha, anti-C5).
- Compare the mechanisms and toxicities of calcineurin inhibitors (Cyclosporine vs Tacrolimus) and mTOR inhibitors (Sirolimus).
- Understand the difference between ADCC (NK cells) and opsonization (macrophages) in immune clearance.
- Recognize the specific roles of thrombopoietin/IL-11 analogs in treating thrombocytopenia.